Finance

Beta
Lists
SABS:NASDAQ
SAB Biotherapeutics Inc
$3.80
-1.81%
(-0.070) 1D
$3.81
+0.26% (+0.0100)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
$3.81
High
$3.95
Low
$3.68
Mkt. cap
290.56M
Avg. vol.
770.20K
Volume
5.65M
52-wk high
$6.60
52-wk low
$1.67
EPS
-$1.43
Beta
0.54
Shares outstanding
76.46M
No. of employees
86
Open
$3.81
High
$3.95
Low
$3.68
Mkt. cap
290.56M
Avg. vol.
770.20K
Volume
5.65M
52-wk high
$6.60
52-wk low
$1.67
EPS
-$1.43
Beta
0.54
Shares outstanding
76.46M
No. of employees
86
News stories
From sources across the web
About SAB Biotherapeutics Inc
CEO-
Employees86
Founded2014
HeadquartersMiami Beach, Florida, United States
SectorBiotechnology
Websitesab.bio
Analyst ratings
Based on 9 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current $3.80
$16.00 (+321.05%)
Average
$12.11 (+218.68%)
Lowest
$6.00 (+57.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eliana Merle
Barclays
Buy
Initiated
$13.00
+242.1%
06/24/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$16.00
+321.1%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$6.00
+57.9%
06/16/2026
Samantha Semenkow
Citi
Buy
Reiterated
$11.00
+189.5%
06/15/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$14.00
+268.4%
06/15/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$10.00
+163.2%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
$11.00
+189.5%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$15.00
+294.7%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$13.00
+242.1%
04/02/2026
Michael Yee
UBS
Buy
Maintained
$7.00
+84.2%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
7.00M
8.97M
9.73M
13.40M
Cost of revenue
7.00M
8.97M
9.73M
13.40M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.74M
3.71M
6.04M
6.60M
Operating expense
2.74M
3.71M
6.04M
6.60M
Total operating expenses
9.73M
12.68M
15.77M
20.00M
Operating income
-9.73M
-12.68M
-15.77M
-20.00M
Other non operating income
-331.43K
57.51M
-1.73M
144.40K
EBT including unusual items
-10.11M
45.45M
-16.86M
-18.87M
EBT excluding unusual items
-10.11M
45.45M
-16.86M
-18.87M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10.11M
45.45M
-16.86M
-18.87M
Net profit margin
-
-
-
-
Earnings per share
-
-
-0.41
-
Interest and investment income
13.56K
655.23K
700.74K
1.05M
Interest expense
-64.34K
-43.29K
-63.46K
-62.74K
Net interest expenses
-50.78K
611.94K
637.28K
984.45K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.96M
-11.91M
-15.01M
-19.25M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of SABS
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer